Edition:
India

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

18.29USD
2:29am IST
Change (% chg)

$-0.24 (-1.30%)
Prev Close
$18.53
Open
$18.48
Day's High
$18.76
Day's Low
$17.96
Volume
55,716
Avg. Vol
124,774
52-wk High
$31.23
52-wk Low
$8.10

Latest Key Developments (Source: Significant Developments)

Akcea Initiates Phase 2b Study Of Hypertriglyceridemia And Established Heart Disease Treatment
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Akcea Therapeutics Inc ::AKCEA INITIATES PHASE 2B STUDY OF AKCEA-APOCIII-LRX IN PATIENTS WITH HYPERTRIGLYCERIDEMIA AND ESTABLISHED CARDIOVASCULAR DISEASE.AKCEA THERAPEUTICS INC - ‍ ANTICIPATES REPORTING TOP-LINE DATA FROM PHASE 2B OF AKCEA-APOCIII-L(RX)​ STUDY IN 2019.  Full Article

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Akcea Therapeutics Inc :Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias.Akcea Therapeutics Inc - ‍AKCEA-ANGPTl3-L(Rx )is designed to reduce production of angiopoietin-like 3, or ANGPTL3​.  Full Article

Akcea Therapeutics Q3 loss per share $0.27
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Akcea Therapeutics Inc :Q3 loss per share $0.27.Akcea Therapeutics Inc qtrly ‍revenue $13.4 million​.Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS